Sanofi SA ADR SNY
News
Trending: Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit — Update
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
Fulcrum Therapeutics, Sanofi Ink Losmapimod Licensing Deal
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
France Secures Billions at Foreign Investment Summit
Sanofi to Spend $1.08 Billion to Boost Drug Production in France
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
Novavax shares more than double on Sanofi's $1.4 billion investment for combo vaccine
Trending: Sanofi, Novavax to Develop New Covid-19 Vaccines
Novavax Shares Surge on $1.4 Billion Vaccine Licensing Deal with Sanofi
Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines
Sanofi Sales, Profit Beat Expectations
Sanofi Says Blood-Disorder Drug Meets Key Target in Late-Stage Trial
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration
Diabetes medication appears to slow progress of Parkinson's disease in French-backed trial
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in COPD
Sanofi Proposes Appointment of New Independent Directors